曲妥珠单抗1治疗HER-2过表达乳腺癌的研究进展  

The Research Progress of Herceptin in Treatment of HER-2 Overexpressing Breast Cancer

作　　者：陈贤玉[1] 王昆华[2] 

机构地区：[1]昆明医科大学云南省肠外肠内营养研究中心,云南昆明650031 [2]昆明医科大学第一附属医院,云南昆明650032

出　　处：《昆明医科大学学报》2013年第12期145-148,共4页Journal of Kunming Medical University

基　　金：国家自然科学基金资助项目(81360069);云南省自然科学基金资助项目(2010CD196)

摘　　要：原癌基因的激活和抑癌基因的失活是肿瘤形成的重要分子机制.原癌基因HER-2是与乳腺癌的侵袭,转移及预后密切相关,HER-2过表达型乳腺癌进展快,预后差.近年来,针对HER-2结构构建具有靶向治疗作用的单克隆抗体药物曲妥珠单抗出现,显著提高了HER-2阳性晚期乳腺癌的疗效.Oncogene activation and inactivation of tumor suppressor genes is an important molecular mechanism of tumor formation. HER-2 oncogene is associated with breast cancer invasion and metastasis and prognosis, HER-2 overexpressing breast cancer progresses rapidly and has poor prognosis. In recent years, the emergence of targeted therapeutic monoclonal antibody drug Herceptin which built its structure for the HER-2 has significantly inproved HER-2-positive advanced breast cancer.

关 键 词：乳腺癌 HER-2基因 曲妥珠单抗 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]